Elekta AB (publ) (OTCMKTS:EKTAY – Get Free Report) was the recipient of a large decline in short interest in February. As of February 28th, there was short interest totalling 100 shares, a decline of 66.7% from the February 13th total of 300 shares. Based on an average daily volume of 17,600 shares, the short-interest ratio is currently 0.0 days. Currently, 0.0% of the shares of the stock are short sold.
Elekta AB (publ) Price Performance
OTCMKTS:EKTAY traded up $0.25 during midday trading on Friday, hitting $5.60. The company had a trading volume of 16,942 shares, compared to its average volume of 9,312. Elekta AB has a 52-week low of $5.25 and a 52-week high of $8.24. The stock’s fifty day moving average price is $5.75 and its 200-day moving average price is $6.01. The company has a market capitalization of $2.15 billion, a PE ratio of 22.39 and a beta of 1.25. The company has a quick ratio of 0.81, a current ratio of 1.05 and a debt-to-equity ratio of 0.60.
Elekta AB (publ) (OTCMKTS:EKTAY – Get Free Report) last announced its earnings results on Friday, February 21st. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01). Elekta AB (publ) had a return on equity of 11.07% and a net margin of 5.65%. The company had revenue of $416.86 million during the quarter, compared to analysts’ expectations of $435.89 million. As a group, research analysts expect that Elekta AB will post 0.36 earnings per share for the current year.
Elekta AB (publ) Cuts Dividend
Wall Street Analysts Forecast Growth
Separately, Sanford C. Bernstein upgraded shares of Elekta AB (publ) from a “strong sell” rating to a “hold” rating in a research report on Wednesday, January 29th.
Get Our Latest Research Report on Elekta AB (publ)
Elekta AB (publ) Company Profile
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services.
See Also
- Five stocks we like better than Elekta AB (publ)
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Elekta AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elekta AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.